Floatz logo

Therapeutic Asset Ratings

223 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Carboplatin
Lung Cancer
SystImmune Inc.P4BB (70)
CIS-DIAMMINEDICHLOROPLATINUM II
Lung Cancer
University of VermontP4BB (70)
Nivolumab
Lung Cancer
University of ChicagoP4BB (69)
ETOPOSIDE
Lung Cancer
SystImmune Inc.P3BB (69)
Docetaxel
Lung Cancer
SWOG Cancer Research NetworkP3BB (68)
Irinotecan
Lung Cancer
City of Hope Medical CenterP3BB (68)
Vinorelbine
Lung Cancer
Alliance for Clinical Trials in OncologyP3BB (68)
Gefetinib
Lung Cancer
Fuzhou General HospitalP3BB (67)
Cyclophosphamide
Lung Cancer
City of Hope Medical CenterP3BB (66)
Hycamtin
Lung Cancer
Fox Chase Cancer CenterP3BB (66)
Ipilimumab
Lung Cancer
University of ChicagoP4BB (65)
Eloxatin
Lung Cancer
Tango Therapeutics, Inc.P2/3BB (65)
DEXAMETHASONE
Lung Cancer
SWOG Cancer Research NetworkP4BB (64)
Nicotine
Lung Cancer
Ohio State University Comprehensive Cancer CenterP4BB (64)
Epirubicin
Lung Cancer
City of Hope Medical CenterP3BB (64)
(+)-VINCRISTINE
Lung Cancer
City of Hope Medical CenterP3BB (64)
FLUTICASONE
Lung Cancer
University of WashingtonP2BB (64)
Atezolizumab
Lung Cancer
University of WashingtonP4B (63)
PREDNISONE TABLETS
Lung Cancer
PfizerP4B (63)
Catequentinib
Lung Cancer
Shanghai Chest HospitalP3B (63)
Osimertinib
Lung Cancer
Beijing Pearl Biotechnology Limited Liability CompanyP3B (63)
Tislelizumab
Lung Cancer
Gustave Roussy, Cancer Campus, Grand ParisP3B (63)
Sargramostim
Lung Cancer
University of WashingtonP2B (63)
Thalidomide
Lung Cancer
Tongji UniversityP4B (62)
Cediranib
Lung Cancer
City of Hope Medical CenterP3B (62)
Showing 1 to 25 of 223 assets
PreviousPage 1 of 9Next